bringing minimal residual disease (mrd) measurement to the clinic
Published 6 years ago • 246 plays • Length 3:28Download video MP4
Download video MP3
Similar videos
-
2:57
when is the optimal time to measure minimal residual disease (mrd) in myeloma patients?
-
3:19
what impact have new minimal residual disease (mrd) assessment techniques had in myeloma?
-
1:49
bringing precision medicine and mrd into clinical strategies
-
1:39
minimal residual disease (mrd) monitoring for multiple myeloma is here to stay
-
1:27
using mrd to guide treatment decisions in the clinic
-
4:05
are we ready to use minimal residual disease (mrd) to direct multiple myeloma therapy?
-
3:40
what’s new in minimal residual disease (mrd) detection in myeloma?
-
4:35
learn about measurable residual disease (mrd)
-
7:54
patient/caregiver stories - living with mds
-
1:35:54
the future is now in mds: integrating innovative, risk-adapted therapies into patient management
-
2:30
unmet needs in ptcl: improving frontline therapy and personalizing treatment
-
3:01
minimal residual disease: a key determinant of all treatment response
-
2:35
mrd focus: why measurable residual disease testing is the future
-
3:07
minimal residual disease (mrd)
-
5:10
how is minimal residual disease (mrd) measured?
-
2:05
using mrd negativity to measure depth of response & to discontinue treatment in multiple myeloma
-
1:17
mrd measurement as a strategy for treatment-free survival
-
2:18
new applications for mrd measurement in myeloma: mrd 'over time'
-
1:50
treatment of minimal residual disease in aml patients
-
2:17
the benefit of detecting minimal residual disease in mm
-
2:12
barriers to the implementation and standardization of ai in the clinic
-
3:35
minimal residual disease (mrd) as a prognostic factor for acute myeloid leukemia (aml)